8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   February 6, 2007   

Zynex Medical Holdings, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	33-26787-D	90-0275169
(State or other	(Commission	(I.R.S. Employer
jurisdiction of incorporation)	File Number)	Identification No.)

8100 South Park Way, Suite A-9, Littleton, CO  80120

(Address of principal executive offices)  (Zip Code)

Registrant’s telephone number:  (303) 703-4906

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On February 6, 2007, Zynex Medical Holdings, Inc. issued a press release regarding unit orders for the fourth quarter of 2006 and the month of January, 2007. The press release is attached as an exhibit to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Document

99.1    Press Release of Zynex Medical Holdings, Inc. dated February 6, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on as its behalf by the undersigned hereunto duly authorized.

	Zynex Medical Holdings, Inc.             (Registrant)
Date: February 8, 2007	By:	/s/ Thomas Sandgaard
		Thomas Sandgaard President and Chief Executive Officer

Exhibit No. Document

99.1    Press Release of Zynex Medical Holdings, Inc. dated February 6, 2007

EX-99.1

Exhibit 99.1

Press Release

February 5, 2007

Comments 2/5

Zynex Announces Increased Orders

Zynex Medical Holdings, Inc. Littleton, Colorado (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 337% for January of 2007 compared to the same month last year and a 172% increase in orders during 4^th quarter of 2006, compared to the 4^th quarter of 2005.

Thomas Sandgaard, CEO, states: “We are pleased to see that our expanded sales force continues to increase sales and rentals and leverage their industry experience to keep building a significant position in the market for Zynex. We expect to see an increase in orders in the foreseeable future when compared to the same periods in 2006”.

Zynex received 590 orders in January, 2007 versus 135 orders twelve months ago and 1,029 orders in 4^th quarter of 2006 versus 378 orders in the 4^th quarter of 2005, respectively.

Zynex has not yet finalized its results for the fourth quarter of 2006 and the 2006 year, including the impact of increased sales and rentals. Zynex will state these results in the Form 10-KSB for the 2006 year.

About Zynex Medical Holdings, Inc.

Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, risks and delays associated with product development, risk of market acceptance of products, technology or product obsolescence, competitive risks, reliance on manufacturing partners, dependence on reimbursement from insurance companies, additional capital needs and other risks described in our Form 10-KSB for the year ended December 31, 2005.

Contact Information

Zynex Medical

Thomas Sandgaard, CEO

(303) 703-4906

www.zynexmed.com